New research indicates that people who come off new slimming jabs like Mounjaro or Wegovy may regain lost weight at a significantly accelerated pace than those who stop conventional lifestyle plans.
Findings released in a prominent health publication points out that while obese individuals can lose substantial amounts of their total mass while on the medication, the weight comes back at an average rate of nearly a kilo each month once they quit.
"People purchasing such treatments must be aware of the risk of rapid weight regain when the medication ends," stated researcher Dr. Susan Jebb.
This pace of recovery means a reversion to starting weight in about 18 months.
Weighing Approaches
The study, which reviewed dozens of trials involving thousands of participants, compared the outcomes of GLP-1 agonists with other pills.
Researchers note that people who lose weight through lifestyle changes alone generally see a less rapid weight regain—perhaps 100 grams monthly—after stopping.
The Reason for the Rapid Regain
Doctors believe the way of the drugs explains the heightened rebound.
The injections imitate a body's own chemical called GLP-1, which helps regulate appetite.
"Long-term administration of the hormone concentrations far above than the body's typical production may cause the system to generate a reduced amount of its own natural hormone, and could lessen sensitivity to its actions," said Dr. Adam Collins, a dietetics researcher.
"Stopping of this GLP-1 'fix' results in appetite is uncontrolled, making binge eating far more likely."
An Ongoing Issue?
Medical guidelines recommend the jabs for people with obesity-related health risks, alongside recommended lifestyle changes.
Professionals say that, considering the high risk of weight regain, the therapy is often long-term.
This opinion is reinforced by pharmaceutical companies, who note that the findings "highlight the long-term nature of obesity," akin to managing diseases like diabetes.
User Testimonies
People who have come off the jabs report a intense resurgence of cravings.
"It felt as if something that goes on and you're instantly ravenous," said an individual.
This difficulty is compounded if users have not developed lasting dietary or behavioural modifications during treatment.
Growing Interest
Figures suggest that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with demand being substantial.
- Adoption is higher among females than males.
- The 40s and 50s demographic shows the highest level of interest.
- Many access the drugs through private healthcare rather than public health services.
Ultimately, clinicians caution that while these medications are potent agents for weight loss, they are not a standalone cure and lasting health benefits relies on integrated behavioural management.
